Silodosin
- Generic Name
- Silodosin
- Brand Names
- Rapaflo, Silodyx, Urorec, Silodosin Recordati
- Drug Type
- Small Molecule
- Chemical Formula
- C25H32F3N3O4
- CAS Number
- 160970-54-7
- Unique Ingredient Identifier
- CUZ39LUY82
- Background
Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α subtype accounts for approximately 75% of α1-adrenoceptors in the prostate.
...
- Indication
Silodosin is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). It is not indicated for the treatment of hypertension.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH)
- Associated Therapies
- -
Study of Silodosin to Facilitate Passage of Urinary Stones
- Conditions
- Interventions
- First Posted Date
- 2010-06-16
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Watson Pharmaceuticals
- Target Recruit Count
- 239
- Registration Number
- NCT01144949
- Locations
- 🇺🇸
Watson Investigational Site, Virginia Beach, Virginia, United States
🇺🇸Watson Investigative Site, North Kansas City, Missouri, United States
A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Watson Pharmaceuticals
- Target Recruit Count
- 215
- Registration Number
- NCT00793819
- Locations
- 🇺🇸
Watson Investigational Site, Burien, Washington, United States
Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH
- Conditions
- Interventions
- First Posted Date
- 2006-08-03
- Last Posted Date
- 2009-02-19
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 1228
- Registration Number
- NCT00359905
- Locations
- 🇬🇧
Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, United Kingdom
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-04-27
- Lead Sponsor
- Watson Pharmaceuticals
- Target Recruit Count
- 661
- Registration Number
- NCT00224133
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Watson Pharmaceuticals
- Target Recruit Count
- 462
- Registration Number
- NCT00224120
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Watson Pharmaceuticals
- Target Recruit Count
- 461
- Registration Number
- NCT00224107
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.